Eisai cuts sales outlook on US weakness for Aciphex
This article was originally published in Scrip
Executive Summary
Eisai has cut back its sales forecast for the fiscal year ending March 31st, pointing to the continued impact of the strong yen and generic threats to one of its mainstay products.